NCT03370276View on ClinicalTrials.gov

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

September 4, 2021

Study Completion Date

December 31, 2025

Conditions
Squamous Cell Carcinoma of the OropharynxSquamous Cell Carcinoma of the LarynxSquamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the HypopharynxSquamous Cell Carcinoma of the Paranasal SinusHead and Neck Squamous Cell CarcinomaSquamous Cell CancerHead and Neck Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.

DRUG

Cetuximab

Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.

Trial Locations (3)

30322

Emory University School of Medicine, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

43210

The Ohio State University, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

James and Esther King Biomedical Research Program

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter